The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A 1,3,5-triazine which is substituted by (2-hydroxy-2-methylpropyl)nitrilo, 6-(trifluoromethyl)pyridin-2-yl and [2-(trifluoromethyl)pyridin-4-yl]nitrilo groups at positions 2,4 and 6, respectively. It is an isocitrate dehydrogenase-2 (IDH2) inhibitor which has been approved for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML).
[enasidenib inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]] which results in increased susceptibility to Daunorubicin; enasidenib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]
[enasidenib inhibits the reaction [ABCC1 protein results in increased export of Daunorubicin]] which results in increased susceptibility to Daunorubicin; enasidenib inhibits the reaction [ABCC1 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [ABCC1 protein results in increased export of Daunorubicin]
[enasidenib inhibits the reaction [ABCG2 protein results in increased export of Daunorubicin]] which results in increased susceptibility to Daunorubicin; enasidenib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [ABCG2 protein results in increased export of Daunorubicin]
enasidenib inhibits the reaction [[AKR1C3 protein results in increased reduction of Daunorubicin] which results in increased abundance of daunorubicinol]; enasidenib inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [AKR1C3 protein results in increased reduction of Daunorubicin] enasidenib results in decreased activity of AKR1C3 protein